BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

  News

Isomorphic Labs Raises $5 Billion, with a16z Joining

by Andrii Buvailo, PhD   •   Nov. 17, 2026

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Biotech Ventures   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook    

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, has raised $5 billion in a Series C round. Greenoaks and Sequoia Capital co-led the round, and Andreessen Horowitz (a16z) joined as a new investor. The company announced the funding on 17 November and said it will use the money to scale its AI drug design platform and move its drug candidates toward clinical trials.

Alphabet, Isomorphic's parent company, invested again, as did Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose its valuation. Bloomberg reported on 4 November that the talks valued the company at about $50 billion.

Each round has been bigger than the last. Isomorphic took its first outside money, $600 million, in March 2025. Fourteen months later, a Thrive-led $2.1 billion Series B became the second-largest venture round ever raised by a biotech, behind Altos Labs' $3 billion in 2022. Six months after that, the Series C tops both and takes Isomorphic's external funding to about $7.7 billion.

Much of the new money will go to scaling IsoDDE, the company's AI drug design engine. The announcement also looks beyond design. Isomorphic plans to build its own AI-first translational and clinical development infrastructure to take candidates into trials, alongside new foundational biology models and AI-led bioengineering capacity.

Isomorphic says its pipeline is heading toward the clinic. Its internal programs in oncology and immunology, along with its partnered work, have produced positive preclinical results that set the stage for clinical entry. Its partners include Eli Lilly and Novartis, whose 2024 deals carry potential milestone payments of nearly $3 billion combined, as well as Johnson & Johnson.
Demis Hassabis, Isomorphic's founder and CEO, said the engine is now producing molecules with high precision and speed. Konstantine Buhler, a partner at Sequoia, called the company's work foundational technology for medicine.

For a closer look at how to judge Isomorphic's platform, see BiopharmaTrend's analysis The $50B Question: How Do We Know If Isomorphic's AI Works?

Topic: Biotech Ventures

Isomorphic Labs
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook    

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.

Sign in or create an account